Navigation Links
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Date:10/6/2008

ol in patients diagnosed with significant postoperative inflammation (more than 10 anterior chamber cells), Durezol effectively reduced inflammation and pain. Mean intraocular pressure for all study groups remained within the normal range throughout the study. Durezol is being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating Durezol for the treatment of anterior uveitis.

Dosage and Administration

The recommended dosage and administration of Durezol is to instill one drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and then continue throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week with tapering based on the response.

Important Safety Information

Durezol, like other corticosteroids, is contraindicated in patients with viral diseases of the cornea and conjunctiva, and also in fungal infections or mycobacterial infections of the eye or ocular structures. Prolonged use of corticosteroids may increase the hazard of secondary ocular infections, exacerbate the severity of ocular viral infections, and increase the development of fungal infections of the cornea. It is important to monitor intraocular pressure when using ophthalmic steroids. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacificati
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Inc. (Nasdaq: ISIS ) today reported net income ... and six months ended June 30, 2015, respectively, compared ... million for the same periods in 2014. Isis, significantly ... than $90 million of revenue Isis earned in the ... to license  ISIS-FXI Rx .  Isis increased its cash ...
(Date:8/4/2015)... FLORHAM PARK, N.J. , Aug. 4, ... partnered with University of Massachusetts Medical School,s ... enhancements and support regarding clinical protocols and ... Workflow Platform. Specialty medication ... ArmadaOne and helps to ensure optimal patient ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Jan. 17, 2012 SIPP International Industries Inc. ... food and beverage, hospitality and medical technology industries announced ... FVJ Holdings, a Japanese Consulting firm based in Osaka ... begin generating additional residual revenues within three months.  ...
... HealthCare today announced latest data on its investigational compound ... Co lo r ectal cancer treated with re ... t herapy) trial. The study met its primary ... by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
(Date:8/4/2015)... ... August 05, 2015 , ... In reaction to a ... liquid propane gas (LPG) next to Seneca Lake*, the full Executive Committee of ... resolution that strongly opposes that permit. *, ** , “1199SEIU healthcare workers have ...
(Date:8/4/2015)... ... , ... How cool is it to check in at your favorite place ... feature will soon allow you to do just that. , Ahhaa is releasing the ... now feature. , Users will soon get to share what inspires them about their ...
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, Inc. ... Tissue Banks (AATB) as an Affiliate Member. Exsurco Medical finds this an ... save and improve lives by promoting the safety, quality and availability of donated ...
(Date:8/4/2015)... Boca Raton, FL (PRWEB) , ... August 04, ... ... on-site diagnostic testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, ... momentum but has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at ...
(Date:8/4/2015)... ... , ... Angelina Jolie is in it at age 39. “It” is menopause, ... Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the Southwest’s leading ... menopause. , Myth #1: Menopause only affects old ladies. – Menopause can affect ...
Breaking Medicine News(10 mins):Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 2Health News:Opposition Mounting to Permit Liquid Propane Gas Storage Next to New York’s Seneca Lake 3Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3
... BEACH, N.Y., April 1 Chem Rx Corporation (OTC ... provider of institutional pharmacy services, announced today that it ... its two primary credit facilities as of December 31, ... with all principal and interest payments (other than as ...
... released today by the American Health Information Management ... Reporters, Editors, Publications, Washington, D.C. News Bureaus, Washington ... Management Association (AHIMA) WHAT: 2009 ICD-10 ... April 16-17, 2009 WHERE: ...
... 1 The Quantum Group, Inc. (NYSE Amex: ... has transitioned to Continental Stock Transfer and Trust Company to ... Guillama, Quantum President & CEO, commented, "Continental Stock Transfer has ... a well regarded reputation as a comprehensive and customer-centric company ...
... Could Save Millions on Expensive Social Services ... on-site services for people who are homeless, have a ... the use and cost of expensive public services such ... a new report released Thursday by the Heartland Alliance ...
... Prominent Internet Based Electronic Claims Clearinghouse to ... in Texas and States Activating Mandates PECOS, ... CLAIM.MD, a leading Internet-based electronic claim processing ... Solutions, Inc., a leading supplier of integrated ...
... three-year contract with Mercy Regional Medical Center, the largest hospital in ... Durango, Colorado. MHS will perform this inventory for the 82-bed acute ... valuation process. www.MHSInc.com , ... Fairfield, Connecticut ...
Cached Medicine News:Health News:Chem Rx Corporation in Technical Violation of Three Financial Debt Covenants 2Health News:Chem Rx Corporation in Technical Violation of Three Financial Debt Covenants 3Health News:The Quantum Group Announces Transition to Continental Stock Transfer 2Health News:The Quantum Group Announces Transition to Continental Stock Transfer 3Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 2Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 3Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 4Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 5Health News:CLAIM.MD Adds Jopari Workers' Compensation Connectivity 2Health News:Mercy Regional Medical Center Selects Management Health Solutions, Inc. for Inventory Services 2
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Malaria P.f. Rapid Test Device...
The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
Core Malaria Pv/Pf is a self performing, qualitative, sandwich immunoassay for the detection and differentiation of vivax malaria and falciparum malaria in whole blood samples....
Medicine Products: